Medical
-
GH Research announced that a Phase 2b clinical trial of GH001 inhaled synthetic mebufotenin (5-MeO-DMT) in patients with treatment-resistant depression met its primary endpoint, demonstrating a significant reduction in depression symptoms as measured by the… Read more . . .
-
Inhalon Biopharma announced that it has contracted with hVIVO to conduct a Phase 2a challenge study of nebulized IN-002, an antibody against RSV, now that Inhalon has completed IND-enabling studies. The company said that it… Read more . . .
-
According to Kinaset Therapeutics, the FDA has cleared the company’s IND for a Phase 2b trial of its KN-002 frevecitinib dry powder inhaler. The 12-week Phase 2 trial, which will evaluate 3 doses of dry… Read more . . .
-
Ethris announces results of Phase 1 trial of ETH47 intranasal mRNA therapy, plans for Phase 2a trial
German biotech company Ethris announced that a Phase 1 trial of intranasal ETH47 mRNA therapy in healthy volunteers demonstrated “a clear dose-dependent production of IFNλ [interferon lambda] in the nasal lining fluid exceeding predicted therapeutic… Read more . . .
-
InvisiShield Technologies said that it will speed up its H5N1 / Pan-influenza intranasal antibodies development program in response to recent outbreaks of H5N1 avian flu in mammals. The company says that it can move quickly… Read more . . .
-
Beckley Psytech announced that a Phase 2a study of BPL-003 intranasal synthetic 5-MeO-DMT in people with alcohol use disorder demonstrated “meaningful and sustained reductions in alcohol use” for as long as 3 months post dose,… Read more . . .
-
Ocugen, Inc. announced that the FDA has cleared an IND for a Phase 1 trial of OCU500 vaccine for the prevention of COVID-19, which the company licensed from Washington University in St. Louis in 2022. The… Read more . . .
-
North Carolina-based Belhaven Biopharma announced that it has closed a funding round that raised $11 million for continued development of the company’s Nasdepi intranasal dry powder epinephrine for the treatment of anaphylaxis. The company said… Read more . . .
-
Vistagen has announced the initiation of a Phase 2 repeat dose study of fasedienol nasal spray, which the company is developing for the treatment of social anxiety disorder. The Phase 3 PALISADE-3 and PALISADE-4 trials… Read more . . .
-
Orexo has announced topline results from its OX640-002 PK/PD study of OX640 intranasal dry powder epinephrine in people with allergic rhinitis. According to the company, the study, which was initiated in October 2024, demonstrated that… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland